D-Tryptophan, N-((4-(2-phenyl-2H-tetrazol-5-yl)phenyl)sulfonyl)- | 193809-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: D-Tryptophan, N-((4-(2-phenyl-2H-tetrazol-5-yl)phenyl)sulfonyl)-
• 英文别名: (2R)-3-(1H-indol-3-yl)-2-[[4-(2-phenyltetrazol-5-yl)phenyl]sulfonylamino]propanoic acid
• CAS: 193809-84-6
• 化学式: C₂₄H₂₀N₆O₄S
• 分子量: 488.527
• InChiKey: NLABJQQLMHAJIL-JOCHJYFZSA-N

物化性质

• 沸点：
  793.3±70.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  151
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  5-(4-bromophenyl)-2-phenyl-2H-tetrazole 在 palladium on activated charcoal N-甲基吗啉 、 正丁基锂 、 磺酰氯 、 二氧化硫 、 氢气 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 D-Tryptophan, N-((4-(2-phenyl-2H-tetrazol-5-yl)phenyl)sulfonyl)-
  参考文献：
  名称：

  Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):  N-Sulfonylamino Acid Derivatives

  摘要：

  Various N-sulfonylamino acid derivatives were synthesized and evaluated for their in vitro and in vivo activities to inhibit type IV collagenase (MMP-9 and MMP-2). When the amino acid residue and the sulfonamide moiety were modified, their inhibitory activities were greatly affected by the structure of the sulfonamide moiety. A series of aryl sulfonamide derivatives containing biaryl, tetrazole, amide, and triple bond were found to be potent and highly selective inhibitors of MMP-9 and MMP-2 In addition, these compounds were orally active in animal models of tumor growth and metastasis. These results revealed the potential of the N-sulfonylamino acid derivatives as a new type of candidate drug for the treatment of cancer.

  DOI：

  10.1021/jm9707582

文献信息

• Metalloprotein inhibitors containing nitrogen based ligands
  申请人：Cohen Seth M.

  公开号：US20120135959A1

  公开（公告）日：2012-05-31

  Provided herein metalloproteinase inhibitors containing nitrogen or mixed nitrogen/oxygen donating zinc binding groups. Also provided are pharmaceutical compositions containing the compounds and methods of treating preventing or ameliorating the diseases associated with metalloproteinase activity using the compounds and compositions.

  本文提供了含有氮或混合氮/氧供体锌结合基团的金属蛋白酶抑制剂。还提供了含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗、预防或改善与金属蛋白酶活性相关的疾病的方法。
• COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE
  申请人：Urigen Pharmaceuticals, Inc.

  公开号：EP3110427A1

  公开（公告）日：2017-01-04
• COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS
  申请人：PARSONS C. Lowell

  公开号：US20170189443A1

  公开（公告）日：2017-07-06

  The present invention is directed to a pharmaceutical composition comprising: (1) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.
• [EN] COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE<br/>[FR] COMPOSITIONS DE SELS DE POLYSULFATE DE PENTOSANE POUR ADMINISTRATION PAR VOIE ORALE ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：URIGEN PHARMACEUTICALS INC

  公开号：WO2015127416A1

  公开（公告）日：2015-08-27

  The present invention is directed to a pharmaceutical composition comprising: (1 ) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.
• Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):  <i>N</i>-Sulfonylamino Acid Derivatives
  作者：Yoshinori Tamura、Fumihiko Watanabe、Takuji Nakatani、Ken Yasui、Masahiro Fuji、Tadafumi Komurasaki、Hiroshige Tsuzuki、Ryuji Maekawa、Takayuki Yoshioka、Kenji Kawada、Kenji Sugita、Mitsuaki Ohtani

  DOI：10.1021/jm9707582

  日期：1998.2.1

  Various N-sulfonylamino acid derivatives were synthesized and evaluated for their in vitro and in vivo activities to inhibit type IV collagenase (MMP-9 and MMP-2). When the amino acid residue and the sulfonamide moiety were modified, their inhibitory activities were greatly affected by the structure of the sulfonamide moiety. A series of aryl sulfonamide derivatives containing biaryl, tetrazole, amide, and triple bond were found to be potent and highly selective inhibitors of MMP-9 and MMP-2 In addition, these compounds were orally active in animal models of tumor growth and metastasis. These results revealed the potential of the N-sulfonylamino acid derivatives as a new type of candidate drug for the treatment of cancer.